Concepedia

Author

F.H.J. van den Hoogen

Radboud University NijmegenORCID

Also Known As

Alphons A den Broeder, F H J VAN DEN HOOGEN, F H J Van den Hoogen, F H J van Den Hoogen, F H J van den Hoogen, F H van den Hoogen, F VAN DEN HOOGEN, F Van Den Hoogen, F Van den Hoogen, F van den Hoogen

390

Publications

25K

Citations

64

H-Index

118

Concepts

All Affiliations

Radboud University NijmegenRadboud University Medical CenterSint MaartenskliniekSint MaartenskliniekLeiden University Medical Center
FV

About

F.H.J. van den Hoogen is an author at Radboud University Nijmegen specializing in medicine, rheumatology, and rheumatoid arthritis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

35

4.1K

2

Public Health

3

3

301

3

Engineering

2

2

89

4

Health Sciences

2

2

148

5

Natural Sciences

1

1

13

F.H.J. van den Hoogen

×

173

Publications

22K

Citations

61

H-Index

YearCitations

2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen,

Arthritis & Rheumatism

2013

3.3K

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen,

Annals of the Rheumatic Diseases

2013

2.8K

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

Gerard A. Schellekens, Hendrik Visser, B.A.W. de Jong,

Arthritis & Rheumatism

2000

1.4K

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Gerard A. Schellekens, Brigit A. de Jong, F.H.J. van den Hoogen,

Journal of Clinical Investigation

1998

1.4K

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis

Jacob M. van Laar, Dominique Farge, Jacob K. Sont,

JAMA

2014

725

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

E. J. A. Kroot, B.A.W. de Jong, M. A. van Leeuwen,

Arthritis & Rheumatism

2000

636

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

Otylia Kowal‐Bielecka, Robert Landewé, Jérôme Avouac,

Annals of the Rheumatic Diseases

2009

611

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192

Christopher P. Denton, Peter A. Merkel, Daniel E. Furst,

Arthritis & Rheumatism

2006

449

Autosomal dominant and recessive osteochondrodysplasias associated with the COL11A2 locus

Miikka Vikkula, Edwin C.M Madman, Vincent Chi Hang Lui,

Cell

1995

409

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

Timothy R. D. J. Radstake, Morten Svenson, A M M Eijsbouts,

Annals of the Rheumatic Diseases

2008

377

Page 1